NeuroSense Therapeutics

Company snapshot

Advancing research, development and therapy for ALS and additional CNS indications. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients gl

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for NeuroSense Therapeutics. Not investment advice.

• Peer + 0 momentum

  Denali Therapeutics

  TA overlap score 24.6

• Peer + 0 momentum

  Amylyx Pharmaceuticals EMEA

  TA overlap score 21.4

Recent activity

Latest pipeline, patent, and corporate events for NeuroSense Therapeutics.

1. Jun 8, 2026 Clinical update

   Fixed dose combination Ciprofloxacin/Celecoxib — Phase 2

2. Jun 8, 2026 Clinical update

   Fixed dose combination Ciprofloxacin/Celecoxib — Phase 1

3. Jun 5, 2026 Clinical update

   PrimeC — Phase 2

4. May 23, 2026 Clinical update

   PrimeC — Phase 2

5. May 23, 2026 Clinical update

   PrimeC 748 mg — Phase 1

View all clinical trial activity →

• What is NeuroSense Therapeutics?

  NeuroSense Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker NRSN. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis, Pharmacokinetics, ALS (Amyotrophic Lateral Sclerosis), Alzheimer Disease. NovaPharmaNews l

• Is NeuroSense Therapeutics publicly traded?

  Yes. NeuroSense Therapeutics is listed with ticker NRSN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does NeuroSense Therapeutics develop or market?

  We link 6 drug profile(s) where NeuroSense Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/neurosense-therapeutics#company-drugs.

• What are the latest developments for NeuroSense Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does NeuroSense Therapeutics focus on?

  NeuroSense Therapeutics focuses on Amyotrophic Lateral Sclerosis, Pharmacokinetics, ALS (Amyotrophic Lateral Sclerosis) based on our analysis of their pipeline programs and drug development activities.